Contrasting BioAtla (NASDAQ:BCAB) and Sorrento Therapeutics (OTCMKTS:SRNEQ)

BioAtla (NASDAQ:BCABGet Free Report) and Sorrento Therapeutics (OTCMKTS:SRNEQGet Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Risk & Volatility

BioAtla has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Sorrento Therapeutics has a beta of 2.49, meaning that its stock price is 149% more volatile than the S&P 500.

Valuation & Earnings

This table compares BioAtla and Sorrento Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioAtla $250,000.00 527.34 -$106.48 million ($2.66) -1.03
Sorrento Therapeutics $62.84 million 0.22 -$572.84 million N/A N/A

BioAtla has higher earnings, but lower revenue than Sorrento Therapeutics.


This table compares BioAtla and Sorrento Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioAtla N/A -89.27% -65.19%
Sorrento Therapeutics -852.82% N/A -106.85%

Analyst Ratings

This is a summary of recent ratings and recommmendations for BioAtla and Sorrento Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioAtla 0 0 5 0 3.00
Sorrento Therapeutics 0 0 0 0 N/A

BioAtla currently has a consensus price target of $14.80, indicating a potential upside of 438.18%. Given BioAtla’s higher possible upside, equities research analysts clearly believe BioAtla is more favorable than Sorrento Therapeutics.

Insider & Institutional Ownership

71.7% of BioAtla shares are owned by institutional investors. Comparatively, 0.0% of Sorrento Therapeutics shares are owned by institutional investors. 8.4% of BioAtla shares are owned by insiders. Comparatively, 2.6% of Sorrento Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.


BioAtla beats Sorrento Therapeutics on 8 of the 11 factors compared between the two stocks.

About BioAtla

(Get Free Report)

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

About Sorrento Therapeutics

(Get Free Report)

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Receive News & Ratings for BioAtla Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAtla and related companies with's FREE daily email newsletter.